Chronic inflammatory gastrointestinal diseases such as Crohn's disease (CD) and ulcerative
colitis (UC) are known as inflammatory bowel disorders (IBD). Patients with inflammatory …

Background COVID-19 vaccine-induced antibody responses are reduced in patients with
inflammatory bowel disease (IBD) taking anti-TNF or tofacitinib after two vaccine doses. We …

Background Patients with inflammatory bowel disease (IBD) often require
immunosuppressive therapy and are hence susceptible to various opportunistic viral and …

Background Patients with inflammatory bowel disease (IBD) and healthy controls received
primary SARS-CoV-2-mRNA vaccination and a booster after six months. Anti-TNF-α-treated …

Background Immunocompromised patients have varying responses to SARS-CoV-2 mRNA
vaccination. However, there is limited information available from prospective clinical trial …

Aim There are limited data on the impact of 2 vs 3 doses of COVID-19 vaccine in patients
with inflammatory bowel disease (IBD). The primary aim of the study was to assess the …

51: 1149–59. 7 Blais P, Husain N, Kramer JR, Kowalkowski M, ElSerag H, Kanwal F.
Nonalcoholic fatty liver disease is underrecognized in the primary care setting. AM J …

Background Patients with inflammatory bowel disease (IBD) may have a modified immune
response to SARS-CoV-2. The objectives were to evaluate the prevalence of COVID-19 in …

Background The incidence and severity of coronavirus disease 2019 (COVID-19) among
Crohn's disease (CD) patients are unknown in China. This study aimed to clarify the clinical …

The COVID-19 pandemic has caused extended global disruption and changed healthcare
behaviour and delivery in patients with inflammatory bowel disease, many of whom take …